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ORIGINAL ARTICLE
Platelet increment is not associated with endothelial damage in haematological
patients: a prospective observational study
S. Benediktssona,b , T. Kandera,b , S. R. Ostrowskic , P. I. Johanssonc , O. D. Thomasa,d and
U. Sch€otta,b
aMedical Faculty, Institution of Clinical Sciences Lund, Lund University, Lund, Sweden; bDepartment of Perioperative and Intensive Care,
Skåne University Hospital, Lund, Sweden; cSection for Transfusion Medicine, Capital Region Blood Bank, Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark; dPaediatric Intensive Care Unit, SUS Skåne University Hospital Lund, Lund, Sweden
ABSTRACT
The aim of this study was to investigate if thrombocytopenic haematology patients show signs of
endothelial damage when transfused with platelets and if that damage correlates with platelet incre-
ment measured with corrected count increment (CCI). Endothelial damage secondary to radiation or
chemotherapy may lead to consumption of transfused platelets but research in this field is scarce.
Patients were divided into four groups: Group 1: Acute leukaemia; Group 2: Autologous stem cell
transplantation (SCT); Group 3: Allogenic SCT; and Group 4: patients receiving platelets prior to inter-
ventions. Blood was sampled before (baseline) and immediately after (0 h) transfusion and then at 1,
4, 8, 16 and 24h after transfusion. The biomarkers syndecan-1, soluble thrombomodulin (sTM) and vas-
cular endothelial growth factor (VEGF) were analysed. The plasma concentration differences between
baseline and later sampling times were referred to as delta (D). Fifty-four platelet transfusion events
were studied. All biomarkers were within the normal ranges both before and after the transfusions.
The Dsyndecan-1 increased at 0 h (p¼ .02), but there was no significant correlation between
Dsyndecan-1 and CCI. There was no change in any of the other biomarkers after transfusion compared
to before. There were no differences between the groups and no correlations were found between
CCI and C-reactive protein, Dsyndecan-1, DsTM or DVEGF. There were no signs of endothelial damage
before or after platelet transfusions. A transient significant change in syndecan-1 immediately after
platelet transfusion did not influence platelet count or platelet CCI.
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Introduction
Platelet transfusions were introduced as a therapy for irradi-
ation-induced bone marrow damage after the atomic bomb-
ings in Japan at the end of World War II [1]. Modern
chemotherapy, stem cell transplantation (STC) and onco-
logic irradiation therapies have increased the demand for
platelet transfusions. Alternative therapies with platelet-poor
plasma, artificial platelet substitutes, fibrinogen concentrate,
desmopressin, recombinant activated factor VII or thrombo-
poietin have not been able to replace platelet transfusion as
the first line of choice to treat or prevent bleeding in oncol-
ogy/haematology patients with severe thrombocytopenia [2].
Platelet refractoriness, usually defined as an insufficient
rise in platelet count (PLC), has several aetiologies including
both recipient and storage specific properties (Table 1) [3,4].
Damage to the endothelium by disease, chemotherapy and
radiation has been proposed as an additional mechanism for
platelet transfusion refractoriness [4,5], but no studies on
this subject have been performed.
There are other reasons to suspect that platelet transfu-
sions might impact endothelial function. Firstly, the pooled
platelet concentrates in the studied department have a
median volume of 303ml [6] and that volume is rapidly
transfused. Bolus infusions of fluids can disrupt the glycoca-
lyx [7]. In patients with acute myeloid leukaemia (AML),
glycocalyx shedding after platelet transfusion could be con-
nected to an increase in the platelet activation biomarker
sCD40L [8]. Other concerns are the risks for bacteraemia
(secondary to contamination from the venepuncture cannula
during donation) and transfusion related lung injury
(TRALI) after platelet transfusions. These aspects have not
previously been highlighted in glycocalyx research.
The undamaged endothelium is protected by its inner
multi-layered glycocalyx, which is composed of glycopro-
teins and proteoglycans connected to the endothelial cells,
creating a semi-permeable membrane separating the circu-
lating blood from the endothelium and holding about 30%
of the plasma volume [9]. The undamaged glycocalyx does
not seem to promote platelet adherence even if the platelets
are activated [10] but research in this area is scarce. The
protective glycocalyx and its destruction are increasingly the
focus in different clinical situations [9], but there are no
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studies on the potentially damaging effects of platelet trans-
fusions. Damage to the glycocalyx can be studied by analy-
sing the plasma concentrations of different shedded proteins
[11]. Some of the most analysed are syndecan-1, heparan
sulphate, hyaluronic acid and chondroitin sulphate. For
example, when damaged by sepsis, the glycocalyx loses its
ability to control the movement of fluid and larger mole-
cules, leading to a loss of fluid from the microcirculation
into the interstitium – this is also called capillary leakage
and leads to tissue oedema and organ dysfunction [12].
Shedding of intermediate- and outer-layer glycoproteins
not only leads to hypocoagulability through the release of
the endogenous heparin (heparan) but also offers a hyper-
coagulable unprotected cell surface with thrombotic mani-
festations even if blood laboratory analyses indicate severe
hypocoagulability [9,11]. Shedding also affects the binding
sites for antithrombin III, thrombomodulin and tissue factor
pathway inhibitor – which all have anticoagulant effects in
an undamaged glycocalyx. This hypercoagulability of the
endothelial surface may lead to consumption of platelets.
Corrected count increment (CCI) is a better parameter
than PLC to evaluate platelet increment and refractoriness –
but requires calculation of body surface area and measure-
ment of the number of platelets in the platelet concentrate
bag to be transfused. CCI after platelet transfusion has been
extensively studied [13] and we recently published a pro-
spective study were CCI 24 h after transfusion for the first
time was described as linear in different types of haematol-
ogy patients [6].
Based on the above, this substudy of our original study
on CCI [6] aimed to investigate changes in endothelial cell
markers after platelet transfusion and its relation to platelet
increment in haematological patients.
We hypothesised that increased levels of endothelial bio-
markers after a platelet transfusion, as a sign of endothelial
damage, are associated with platelet increment.
Methods
The present study is a predefined substudy of a previously
published study from our group reporting linear decline of
CCI after platelet transfusion in haematological patients [6].
The study obtained ethical approval from the Regional
Review Board in Lund (registration number 2015/628) and
an approved Biobank (DNR 136, VO IPV, Skane University
Hospital [SUS], Lund). The study was conducted in
compliance with the Declaration of Helsinki and was a-pri-
ori registered as a clinical trial with ClinicalTrials.gov
(Identifier: NCT02601131).
All patients 18 years and older who were treated in the
Haematology Department at Skåne University Hospital in
Lund, Sweden, between 12th of February and 28th of
September 2016 and needing platelet transfusions during
office hours, were eligible for inclusion (Table 2). Bleeding
patients were excluded. The known presence of human
leukocyte antigen antibodies or human platelet antigen anti-
bodies requiring matched platelet transfusion was also
exclusion criterion, however not tested for in all patients.
Other exclusion criteria included conditions and treatments
with a very high demand for platelet transfusions, further
described in the main study [6]. All included patients gave
informed and written consent to participate.
Platelet transfusions were given at the discretion of the
treating physician. According to a standardised protocol for
the department, platelet transfusions were considered if the
morning PLC was below 10 109/L or before interventions
such as insertion of a central venous catheter if PLC was
below 50 109/L.
Blood sampling
Venous blood was sampled using a vacutainer system
(Becton, Dickinson and Company [BD], Plymouth, UK) and
collected into 3ml VacutainerVR spray-coated K2EDTA tubes
(BD) before and directly after the platelet transfusion, and
then at 1, 4, 8, 16 and 24 h after transfusion. The samples
were centrifuged at the accredited central laboratory of the
hospital and the plasma frozen down to –80 C within 2 h
from sample time. Blood was sampled from the central ven-
ous line, if present, after discarding the first 10ml.
Otherwise, blood was retrieved from a peripheral vein. For
each patient, no more than two platelet transfusion events
were studied.
Patient groups
Patients were divided into four groups based on
their condition.
Group 1: Patients undergoing treatment for AML, acute
lymphocytic leukaemia (ALL), mixed phenotype acute
Table 1. Factors affecting platelet increment.
Recipient properties Storage properties
Human Leukocyte Antigen (HLA) antibodies Platelet activation occurring prior to storage and during the preparation
of the platelet concentrate.
Human Platelet Antigen (HPA) antibodies Platelet activation during storage.
Heparin Changes in adenosine triphosphate (ATP) production by platelets during storage.
Hypersplenism Alterations of platelet surface receptors during storage causing
reduced thrombin-induced platelet aggregation.
Bleeding Enhanced effects of nitric oxide (NO) in stored platelets impair platelet aggregation.
Fever Accumulation of platelet microparticles leading to increased thrombosis.
Gamma irradiation Proinflammatory lesions.
Number of platelet transfusions Immunomodulatory lesions.
Storage time
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leukaemia (MPAL) or myelodysplastic syndromes (MDS).
All had received intensive chemotherapy.
Group 2: Patients receiving an autologous SCT.
Group 3: Patients receiving an allogeneic SCT following
either myeloablative conditioning or reduced-intensity
conditioning.
Patients in these groups (1–3) were in a state of bone
marrow aplasia, and all of them had central venous access.
Group 4: Patients scheduled for prophylactic platelet
transfusion prior to insertion of a central venous catheter.
All patients had a morning PLC < 50 109/L.
Control group: Patients who were not scheduled for
platelet transfusion. Patients in this group had a morning
PLC of 10–20 109/L and were not given platelet transfu-
sion but blood samples were taken according to the same
protocol. The control group was necessary to exclude varia-
tions in PLC independent of platelet transfusion.
Platelet concentrates
The platelet concentrates were produced either by direct
apheresis or from donated whole blood using the buffy-coat
method, in which case the pooled platelet concentrates came
from a total of four donors. Both platelet concentrates were
suspended in 200mL platelet additive solution of type PAS-
E (T-PASþ, Terumo BCT). Approximately 1/3 of the vol-
ume in both types of platelet concentrates was plasma. The
PLC in each transfusion bag was measured about 1 h before
the transfusion. For surveillance of bacterial contamination,
a sample of each platelet concentrate was collected aseptic-
ally the day after donation, transferred to a culture bottle
and incubated in an automatic blood culture cabinet
(BACTEC, Becton Dickinson, Franklin Lakes, NJ, USA).
The platelet concentrates were issued for clinical use based
on the negative-to-date principle. All transfused platelet
units were ABO-matched, leucocyte reduced (<1106 leu-
cocytes per unit) and 7 days old.
Corrected count increment
In the present study, platelet increment was measured with
CCI calculated with the formula below [14].
CCI ¼ PosttransfusionPLCPretransfusionPLCð Þ
ð109=LÞ  BodySurfaceArea ðm
2Þ105
PlateletsTransfusedð109=LÞ
Endothelial cell markers
The endothelial cell markers syndecan-1, sTM and H-VEGF
were analysed at the Section for Transfusion Medicine,
Capital Region Blood Bank, Copenhagen University
Hospital. Plasma vials from the blood samples (see above)
were processed through the Department of Laboratory
Table 2. Patient characteristics.
Group 1, n¼ 19 Group 2, n¼ 7 Group 3, n¼ 16 Group 4, n¼ 12 Control group, n¼ 10 All patients n¼
Age - year,
median (q1–q3)
56 (42–68) 51 (37–60) 39 (26–53) 58 (32–75) 53 (36–59) 49 (36–64)
Gender, female - no. (%) 11 (57) 2 (29) 3 (19) 4 (33); 2(20) 22 (34)
Weight – kg,
median (q1–q3)
66 (63–76) 84 (70–93) 80 (72–83) 69 (63–74) 83 (75–99) 74 (66–83)
Height – cm,
median (q1–q3)
173 (164–177) 176 (170–179) 178 (175–183) 176 (168–180) 177 (169–183) 176 (170–178)
Body surface area –
m2, median (q1–q3)
1.8 (1.7–1.8) 1.8 (1.7–1.8) 1.8 (1.7–1.8) 1.8 (1.7–1.9) 2.0 (1.9–2.2) 1.9 (1.8–2.1)
Spleen statusa – no (%)
Enlarged 3 (16) 1 (14) 3 (19) 3 (25) 2 (20) 12 (19)
Primary diagnosis – no (%)
ALLb 1 (5) 0 (0) 2 (12) 3 (25) 0 (0) 6 (9)
AMLc 13 (68) 0 (0) 7 (44) 7 (58) 1 (10) 28 (44)
MDSd 3 (16) 0 (0) 0 (0) 0 (0) 0 (0) 3 (5)
MPALe 2 (11) 0 (0) 2 (12) 0 (0) 0 (0) 4 (6)
Myeloma 0 (0) 4 (58) 0 (0) 0 (0) 3 (30) 7 (11)
Other diagnosis 0 (0) 3 (42) 5 (31) 2 (17) 6 (60) 16 (25)
Temperature C
median (q1–q3)
37.0 (36.7–37.5) 37.2 (36.6–37.7) 37.2 (36.8–37.7) 37.0 (36.6–37.5) 37.0 (36.7–37.4) 37.1 (36.7–37.5)
Laboratory values,
median (q1–q3)
Hb – g/L 96 (87–104) 102 (94–104) 93 (89–96) 82(76–92) 91 (87–106) 93 (87–99)
Leucocytes – 109/L 0.3 (0.1–0.6) 0.1 (0.1–0.1) 0.1 (0.1–0.2) 0.9 (0.6–4.2) 0.6 (0.2–1.8) 0.3 (0.1–0.7)
CRP –mg/L 36 (11–89) 142 (61–260) 33 (10–109) 33 (7–108); 22 (4–48) 41 (13–101)
Creatinine - lmol/L 63 (51–74) 64 (47–75) 56 (52–65) 78 (57–105) 67 (59–72) 63 (55–73)
Group 1: Patients receiving chemotherapy with diagnoses of acute myeloid leukaemia, acute lymphoblastic leukaemia, MDS or MPAL. Group 2: Patients under-
going autologous stem cell transplantation during current admission. Group 3: Patients undergoing allogeneic stem cell transplantation during current admis-
sion. Group 4: Patients receiving platelet transfusion before interventions.
aThe estimation was done using abdominal CT-scan or ultrasound if performed (30/54 cases) otherwise the documented clinical examination at admission was
used. No patients were splenectomised.
bAcute Lymphoblastic Leukaemia.
cAcute Myeloid Leukaemia.
dMyelodysplastic Syndrome.
eMixed Phenotype Acute Leukaemia.
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Medicine, SUS, Lund. Ethylenediaminetetraacetic acid
(EDTA) blood was centrifuged twice at 1800 g and 5 C
for 10min each and stored at –86 C until analysis.
The endothelial cell markers were measured by commer-
cially available immunoassays in accordance with the manu-
facturer’s recommendations.
Syndecan-1
Syndecan-1 is a heparan sulphate proteoglycan and one of
the glycocalyx components. Syndecans govern cell adhesion,
cell signalling and organisation of the cytoskeleton. The syn-
decan-1 protein participates in cell proliferation, cell migra-
tion and cell-matrix interactions through its receptor for
extracellular matrix proteins.
Syndecan-1 was analysed with an enzyme-linked
immunosorbent assay (ELISA; Nordic Biosite, Copenhagen,
Denmark); the lower limit of detection (LLD) was 4.94ng/ml.
The normal reference range was 15–47ng/ml. The inter-/
intra-assay variability for syndecan-1 was 10.2%/6.2%.
sTM
Thrombomodulin (sTM) is a membrane protein expressed
on the surface of endothelial cells that works as a cofactor
for thrombin. The thrombomodulin-thrombin complex
(TT-complex) raises the speed of protein C activation by a
1000-fold and thereby works as an anticoagulant.
Inflammatory cytokines downregulate thrombomodulin, and
activated leukocytes can cleave thrombomodulin, releasing it
into the circulation as soluble thrombomodulin (sTM), a
less active form. Elevated levels of sTM in the blood can be
seen as a sign of endothelial cell damage.
sTM was analysed with ELISA (Nordic Biosite,
Copenhagen, Denmark); the LLD was 0.31 ng/ml. The nor-
mal reference range was 2.39–7.9 ng/ml. The inter-/intra-
assay variability for the sTM assay was 9.8%/3.9%.
H-VEGF
Vascular endothelial growth factor (VEGF) is a signal pro-
tein and a member of the platelet-derived growth factor
family. VEGF exerts its biological effects by binding and
activating its different tyrosine-kinase receptors to endothe-
lial cells, eventually leading to their proliferation, migration
and increased permeability. VEGF induces embryonic vessel
development as well as physiological and pathological angio-
genesis. Most of the circulating VEGF resides in platelets.
When platelets become activated at a site of injury, they
release their stored VEGF, which binds to and activates
endothelial cells so the wound can heal completely. VEGF is
also bound to the glycocalyx and is released during glycoca-
lyx shedding.
Human VEGF was analysed with ELISA (QuantikineVR ,
R&D Systems Europe, Ltd., Abingdon, UK); the LLD was
31.3 pg/ml. The normal reference range was P-VEGF-
A< 80 pg/ml. The inter-/intra-assay variability for the P-
VEGF-A assay was 7%/<5%.
C-reactive protein
C-reactive protein (CRP) was analysed with a lithium-hep-
arin tube (LH PST, BD VacutainerVR systems, Plymouth,
UK). The normal reference range for CRP was <3.0mg/L,
imprecision 4.4%.
Statistics
Statistical analyses of the collected data were performed
using GraphPad Prism 7.00 (GraphPad Software, La Jolla,
CA, USA). Non-parametric methods were used since the
endothelial cell markers were not normally distributed.
Concentrations of endothelial cell markers measured dir-
ectly before the platelet transfusions were set as baseline.
The differences in the plasma concentrations at baseline and
directly after the platelet transfusion (0 h) were referred to
as delta (D).
Analyses of differences in concentrations over time were
performed with Friedman test. Concentrations from all
times were compared with the concentration before transfu-
sion using Dunn’s multiple comparisons test.
The Kruskal-Wallis test was used to compare the D con-
centrations of the endothelial cell markers between the
patient groups as well as for comparisons of the endothelial
cell markers between the groups at the baseline.
Correlation analyses were calculated using Spearman’s
correlation tests.
p Values <.05 were considered significant.
Results
The study entailed 54 platelet transfusion events in 43
patients; group 1, n¼ 19; group 2, n¼ 7; group 3, n¼ 16;
group 4, n¼ 12 and control group, n¼ 10. Patient charac-
teristics are presented in Table 2.
The median volume (interquartile range [IQR]) for the
given platelet concentrates was 303ml (295–313) and the
median platelet count per platelet concentrate (IQR) was
246 109 (203–268) with a minimum of 153 109 and a
maximum of 304 109. Both volumes and counts per plate-
let concentrate were without differences between the buffy-
coat and the apheresis concentrates. Buffy coat concentrates
were given to 48 patients (89%) and apheresis concentrates
were given to 6 patients (11%). The median storage time
(IQR) for the platelet concentrates were 4 days (4–7).
The median CCI (IQR) 1-h post-transfusion was 9624
(7663–13367). Platelet refractoriness defined as CCI < 5000
1 h after transfusion, was found in three cases.
The changes in concentrations of the endothelial cell
markers up to 24 h after transfusions were compared to
baseline (Figure 1). The level of syndecan-1 was elevated
immediately after the platelet transfusion compared to the
baseline (p¼ .02), but no significant differences were found
at any other investigated time compared to baseline. There
was no significant increase in sTM or VEGF compared to
the baseline at any investigated time.
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Two different analyses were performed to investigate if
the pre-defined groups differed regarding endothelial cell
markers. First, concentrations at baseline were compared
between groups (control, 1–4; Figure 2). There were no sig-
nificant differences in concentrations of syndecan-1 and
sTM. VEGF-concentrations however differed between the
groups at baseline (p¼ .02). All three analysed endothelial
cell markers were within normal reference values at baseline.
Second, D concentrations of endothelial cell markers from
before to directly after the platelet transfusion (Figure 3)
between groups 1–4 were compared (Figure 3). No signifi-
cant differences were found between the groups.
There were no correlations between CCI and CRP, D
syndecan-1, D sTM or D VEGF (Figure 4).
Discussion
Changes in endothelial cell markers are not associated with
platelet increment in haematology patients: our hypothesis
was disproven.
Pre-transfusion plasma concentrations of the endothelial
cell markers syndecan-1, sTM and VGEF were within the
normal range. There was only a transient rise in syndecan-1
immediately after the platelet transfusion compared to base-
line values; levels were still within normal values. This result
could be a passive transfer of increased endothelial cell
markers in stored platelet concentrates; the longer the stor-
age period, the higher the concentration of endothelial cell
markers, as has been described for VEGF [15]. This is how-
ever not likely for syndecan-1 as this biomarker is not shed
from platelets and plasma is diluted by platelet additive
solution and previous studies have demonstrated lower-
than-normal plasma levels in platelet concentrates [8].
Consequently, transfusing a bag of 250ml platelet con-
centrate to a human with a blood volume of 4–5 L would
probably not affect the syndecan-1 plasma concentration.
This is in accordance with Larsson et al. who did not find
any significant changes in syndecan-1 and sTM up to 24 h
after platelet transfusion in patients with AML, correspond-
ing to Group 1 in this study. However, they did find a posi-
tive correlation between the platelet activation biomarker
sCD40L’s plasma level 1 h after transfusion and increased
syndecan-1 and sTM D values [8].
Normally, the intact glycocalyx protects the endothelium
from activated platelets; therefore, signs of both a damaged
glycocalyx and activated platelets probably need to be pre-
sent to have an additive effect. Although platelet concen-
trates may have slightly increased concentrations of different
shedded glycocalyx glycoproteins (passive transfer from the
donor plasma), their role is unknown.
Syndecans are important regulators of human carcino-
genesis and work as cell surface receptors. In humans, syn-
decans 1–4 interact in leukocyte rolling on endothelial cells,
wound repair, angiogenesis, carcinogenesis, vascular perme-
ability and modulation of chemokine activity [16]. It is not
Figure 1. Plasma concentrations of the different endothelial cell markers
varying over time. Groups 1–4 aggregated. Friedman test revealed a p
value of .02 for differences between all time points for syndecan-1.
Concentrations of the endothelial cell markers at the baseline (before plate-
let transfusion) were compared with concentrations from all other times
(0, 1, 4, 8, 16 and 24 h post-transfusion) using Dunn’s multiple comparisons
test, which showed a p value of .02 for syndecan-1 directly after transfu-
sion (0 h). The numbers in the squares represent significance for Friedman
tests. N.S.: non-significant; sTM: soluble thrombomodulin; VGEF: vascular
endothelial growth factor.
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yet clear whether shedded syndecans are directly involved in
causing cancer or whether they have positive or negative
roles in carcinogenesis. Our study did not find increased
Figure 2. Comparison of plasma concentrations of the endothelial cell
markers at baseline between groups Kruskal–Wallis test. Group 1: Patients with
AML, ALL, MPAL or MDS. Group 2: Patients receiving autologous SCT. Group 3:
Patients receiving allogeneic SCT. Group 4: Patients scheduled for prophylactic
platelet transfusion prior to insertion of a central venous catheter. Control
group: Patients not scheduled for platelet transfusion. N.S.: non-significant.
Figure 3. Comparison of D concentrations of the endothelial cell markers
(i.e. the difference in concentration before versus directly after the comple-
tion of the platelet transfusion [before 0 h]) stratified by groups.
Kruskal–Wallis test was used for the comparisons. Group 1: Patients with
AML, ALL, MPAL or MDS. Group 2: Patients receiving autologous SCT.
Group 3: Patients receiving allogeneic SCT. Group 4: Patients scheduled for
prophylactic platelet transfusion prior to insertion of a central venous cath-
eter N.S.: non-significant. Zero hours after transfusion: directly after transfu-
sion. s-TM: soluble thrombomodulin; VGEF: vascular endothelial
growth factor.
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plasma concentrations beyond normal ranges for the
respective endothelial cell markers.
Numerous conditions include increased glycocalyx shed-
ding: hypervolemia, inflammation, sepsis, diabetes, renal
failure, atherosclerosis, cardiac arrest, acute decompensated
heart failure, ischaemia/reperfusion, trauma, haemorrhagic
shock and surgery [10,11,17,18]. None of our patients had
such conditions except Group 2, which had some patients
with increased CRP [6]. We found no correlation between
CRP and CCI in the present study.
It has been suggested that endothelial damage secondary
to radiation or chemotherapy may consume transfused pla-
telets and therefore cause platelet refractoriness [4]. We
found neither increased plasma concentrations above upper
normal reference values in the endothelial cell markers we
used, nor significant correlations with CCI. We found no
signs of platelet-induced endothelial damage. There were no
differences in the present study between the four groups
receiving platelet transfusions and the control group which
did not receive platelet transfusions.
One study reported an association between high synde-
can-1 levels and bleeding and endothelial damage in 22
of 49 patients with acute leukaemia [19]. Median synde-
can-1 plasma concentrations (IQR) were 46 ng/ml
(30–102) in the group with bleeding and 27 ng/ml
(21–57) in patients with no bleeding. Patients with more
bleeding also had lower PLCs and lower levels of the
platelet activation marker sCD40L as discussed above.
Other markers of platelet activation and platelet function
were also lower. Even if there were higher plasma con-
centrations of several procoagulative endothelial bio-
markers, patients still bled. These patients were also older
and had higher leukocyte counts. This outcome reflects
the complex picture of in vivo haemostasis: complexity
increases further when glycocalyx and endothelial cell dys-
functions are involved.
Patients with pulmonary embolism (PE) often show a
hypercoagulative plasma coagulation marker profile, but gly-
cocalyx shedding and a damaged endothelial barrier could
also be risk factors. One group demonstrated using receiver
operating characteristics (ROC), that syndecan-1 predicted
high-risk PE with a significant area under the curve (AUC)
of 0.93 [20]. Risk stratification was made using the
European Society of Cardiology’s guidelines for categorising
high, intermediate and low risk. This classification is based
on how the PE effects the patient’s physiologic response,
not the severity of its pathophysiology. In the high-risk PE
category, the median syndecan-1 was 118.6 ng/ml
(range 76.2–133.3).
The same group reported sTM plasma levels correspond-
ing to 3.6 ng/ml (range 2.0–8.2), close to the levels reported
in our study [20]. sTM is not as frequently analysed as syn-
decan-1 [21]. Inflammatory cytokines downregulate throm-
bomodulin, and activated leukocytes can cleave
thrombomodulin, releasing it into the circulation as sTM, a
less active form.
(A) (B)
(C) (D)
Figure 4. Scatterplot showing Spearman correlations between CCI and (A) C-reactive protein (CRP) mg/L; (B) D syndecan-1; (C) D soluble thrombomodulin (sTM)
and (D) D vascular endothelial growth factor (VEGF). All D concentrations refer to differences between baseline and directly after the platelet transfusions (0 h).
N.S.: non-significant.
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Very high levels of syndecan-1 have been reported in
trauma patients compared to healthy controls [22]. Patients
with low colloid osmotic pressure (COP) had the highest
levels of several shedded glycocalyx markers, as did those
with the highest severity injury scores. The median concen-
tration of syndecan-1 (IQR) for the healthy controls was
31.6 ng/ml (16.3–46.9), while those for patients with normal
and low COP were 34.6 ng/ml (19.3–43.1) and 221.7 ng/ml
(88.3–477.4), respectively. One group reported worse out-
comes for trauma patients with syndecan-1 plasma levels
>40 ng/ml and a ROC AUC of 0.71 [21]. sTM in these
patients had a median concentration (IQR) of
6.7 ng/ml (5.4–9.4).
Albumin is the primary protein in blood that maintains
the COP. An albumin-protective effect by mechanisms other
than COP has been proposed, such as an optimally resusci-
tated plasma volume [23]. Another possible mechanism is
the glycocalyx-restoring effect of sphingosine 1-phosphate,
an erythrocyte-derived biomarker that binds to albumin,
possibly explaining the glycocalyx-shedding protective effect
of plasma or albumin infusion therapies and their role in
decreasing mortality in trauma and massive transfusions
[24]. However, in these situations, overtransfusion resulting
in hypervolemia increases the release of atrial natriuretic
peptide, which can increase glycocalyx shedding [25]. It can-
not be ruled out that the (small) volume load induced by
platelet transfusion may contribute to the discrete increase
in syndecan-1 immediately after the transfusion.
Alternatively, the small transient syndecan-1 increase imme-
diately after platelet transfusion could be related to the
platelet storage solution (PAS) and/or activated platelets, if
so – indicating a hit on the glycocalyx.
The baseline levels of VEGF varied significantly among
the groups. Group 4 had the highest levels. It is well known
that solid tumours can express VEGF and thus promote
angiogenesis, which is necessary for tumour growth and
spread. Increasing evidence has emerged that the same is
true for some haematological malignancies. Studies have
shown increased vascularisation in the bone marrow in
patients with AML and, further, that tumour cells in AML
and other haematologic malignancies and malignant plasma
cells in multiple myeloma express and secrete VEGF
[26–28]. Different levels of VEGF expression could therefore
influence VEGF plasma levels.
However, there is another possible explanation for these
differences. Patients in Group 4 had a higher PLC at the
baseline prior to platelet transfusion. Platelets contain VEGF
and release it when activated, and several studies have
shown a correlation between PLC and plasma/serum levels
of VEGF in non-haematology cancer patients [29–31].
Blood samples in Group 4 were retrieved via peripheral ven-
ous cannulation, which may activate platelets more than
when blood is collected from a large-bore central venous
catheter through p-selectin release [32]. Increased levels of
p-selectin correlate to higher VEGF [33].
One of the limitations in the present study is that it is a
single centre study. Second, it has to be mentioned that the
lack of significant differences both when comparing before
and after concentration and the in-between groups compari-
sons should be interpreted with caution. The sample size
calculations in the main study were performed for the
change in PLC after transfusion and therefore the number
of observations in the present study may not be
adequate [6].
In conclusion, a transient significant increase in synde-
can-1 was seen immediately after platelet transfusion, but
with no correlation to CCI. Patients with a higher PLC that
were scheduled for central venous catheterisation had a
higher VEGF before platelet transfusion compared to other
subgroups, which could relate to both the higher PLC and
the increased peripheral vein sampling that occurs before
receiving a central venous catheter. We found no evidence
of endothelial cell barrier defects in our stable thrombocyto-
penic haematology patients either before or after platelet
transfusions.
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